ANKRD10

Across TCGA pan-cancer cohorts, ANKRD10 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ANKRD10 data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher ANKRD10 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ANKRD10 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

LSCC, HNSC, and PDAC are the cancer types where ANKRD10 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	II,III,IV	0.477	0.895	<.001	44	view →
HNSC	OS	Tertile	III,IV	0.867	0.562	.001	42	view →
PDAC	DFS	Median	IV	0.203	0.785	.010	6	view →
LUAD	DFS	Median	III,IV	0.432	0.925	.047	3	view →
CCRCC	DFS	Quartile	III,IV	0.678	0.355	.043	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ANKRD10–LSCC (DFS)

Open the LSCC breakdown →